On November 18, 2015, the U.S. Food and Drug Administration (FDA) approved Narcan nasal spray for the intranasal route for naloxone administration. The intranasal route has been used as an "off-label" method of naloxone administration by the medical community for years. However, the FDA approval of this product created an avenue for pharmaceutical companies to legally manufacture and sell naloxone packaged for the intranasal route of administration.
The naloxone nasal spray has a pre-measured dose of naloxone in a device with a nozzle similar to an over-the-counter nasal spray container. In addition to its use by EMS providers, naloxone nasal spray is also prescribed by healthcare providers or dispensed by pharmacists to laypersons.
As a result of this FDA action, the Ohio Department of Public Safety, Division of Emergency Medical Services has approved a training module designed to assist non-medical first responders with administration of naloxone via intranasal route.
The PowerPoint portion of the training module is available for download below.
If you have any questions, please feel free to contact the Ohio Division of EMS at (800) 233-0785.
Get the latest news and updates directly in your inbox.